Alltrna’s CEO Michelle Warner said that the approach allows for basket trials that can group patients with different diseases ...

Vertex Pharmaceuticals (VRTX) announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use adopted an opinion ...

The companies were two years into a four-year, $400 million agreement aimed at developing and marketing gene therapies ...

Verve offered few details on the early end of a collaboration the companies inked in 2022, saying only that Vertex cited “changing priorities.” ...

The encouraging result comes just days after the US FDA approved Vertex Pharma's non-opioid painkiller Journavx (suzetrigine), an oral NaV1.8 inhibitor, as a treatment for acute pain, representing ...

Vertex Pharmaceuticals exits liver disease gene editing program with Verve Therapeutics. Verve continues work on a separate ...